

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 November 2022 (24.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/245734 A8



(51) International Patent Classification:

C12N 15/86 (2006.01) A61K 48/00 (2006.01)

(21) International Application Number:

PCT/US2022/029452

(22) International Filing Date:

16 May 2022 (16.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/189,552 17 May 2021 (17.05.2021) US
63/219,446 08 July 2021 (08.07.2021) US

(71) Applicants: **CORLIEVE THERAPEUTICS** [FR/FR]; 59 Rue de Ponthieu, 75008 Paris (FR). **REGENXBIO INC.** [US/US]; 9804 Medical Center Drive, Rockville, MD 20850 (US).

(72) Inventors: **HE, Chenxia**; 59 Rue de Ponthieu, 75008 Paris (FR). **PORTER, Richard**; 59 Rue de Ponthieu, 75008

Paris (FR). **MERCER, Andrew**; 9804 Medical Center Drive, Rockville, MD 20850 (US). **DANOS, Olivier**; 9804 Medical Center Drive, Rockville, MD 20850 (US). **TEPE, April, R.**; 9804 Medical Center Drive, Rockville, MD 20850 (US).

(74) Agent: **ARMSTRONG, Richard, Todd**; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: METHODS AND COMPOSITIONS FOR TREATING EPILEPSY

FIG. 1A

Construct A





FIG. 1B



(57) Abstract: Disclosed are methods and compositions relating to antisense therapy for treating epilepsy, such as a temporal lobe epilepsy, in a subject in need thereof by targeting *Grik2* mRNA. In particular, the disclosure provides inhibitory RNA constructs capable of inhibiting expression of GluK2 protein and inhibiting epileptiform discharges in hyperexcitable neuronal circuits.

[Continued on next page]

WO 2022/245734 A8

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

05 January 2023 (05.01.2023)

(15) Information about Correction:

see Notice of 05 January 2023 (05.01.2023)